Related Information

• Simvastatin Information
• Follow-Up to the August 2008 Early Communication About an Ongoing Safety Review of Ezetimibe/Simvastatin (marketed as Vytorin), Simvastatin (marketed as Zocor) and Ezetimibe (marketed as Zetia) - FDA Investigates a Report from the SEAS Trial
  12/22/2009
• Follow-up to the January 25, 2008 Early Communication about an Ongoing Data Review for Ezetimibe/Simvastatin (marketed as Vytorin), Ezetimibe (marketed as Zetia), and Simvastatin (marketed as Zocor)
  1/8/2009
• Early Communication About an Ongoing Safety Review of Ezetimibe/Simvastatin (marketed as Vytorin), Simvastatin (marketed as Zocor) and Ezetimibe (marketed as Zetia) - FDA Investigates a Report from the SEAS Trial (8/21/08) [ARCHIVED]
  8/21/2008
• Information for Healthcare Professionals: Simvastatin (marketed as Zocor and generics), Ezetimibe/Simvastatin (marketed as Vytorin), Niacin extended-release /Simvastatin (marketed as Simcor), used with Amiodarone (Cordarone, Pacerone)
  The FDA notifies the public of the risk of a rare condition of muscle injury called rhabdomyolysis, which can lead to kidney failure or death, when simvastatin is used with amiodarone. (8/8/2008)
• Early Communication about an Ongoing Data Review for Ezetimibe/Simvastatin (marketed as Vytorin), Ezetimibe (marketed as Zetia), and Simvastatin (marketed as Zocor) [ARCHIVED]
  1/25/2008
• Information on Simvastatin/Amiodarone

Labeling and Regulatory History from Drugs@FDA

• Prescribing Information - Ezetimibe/Simvastatin (marketed as Vytorin)

Consumer Information

• Making Sense of Vytorin Concerns
• Ongoing Review of Cholesterol Drug Vytorin
• Controlling Cholesterol with Statins

Contact FDA